Yelena Slinin1,2, Tien Vo3, Brent C Taylor2,3,4, Anne M Murray2,5, John Schousboe6,7, Lisa Langsetmo3, Kristine Ensrud2,3,4. 1. Department of Nephrology, VA Health Care System, Minneapolis, MN, USA. 2. Department of Medicine, University of Minnesota, Minneapolis, MN, USA. 3. Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA. 4. Center for Chronic Disease Outcomes Research, VA Health Care System, Minneapolis, MN, USA. 5. Department of Medicine, Geriatrics Division, Hennepin County Medical Center, Minneapolis, MN, USA. 6. HealthPartners Institute, Bloomington, MN, USA. 7. Division of Health Policy and Management, University of Minnesota, Minneapolis, MN, USA.
Abstract
OBJECTIVE: Determine whether serum phosphate is associated with concurrent cognitive impairment and subsequent cognitive decline in older men independent of demographic covariates and atherosclerotic risk factors. METHODS: In a prospective study of 5529 men enrolled in the Osteoporotic Fractures in Men study, we measured baseline serum phosphate, baseline cognitive function, and change in cognitive function between baseline and follow-up exams an average of 4.6 years later using the Modified Mini-Mental State (3MS) Examination and Trails B. RESULTS: There was no association between serum phosphate and odds of cognitive impairment as assessed by baseline 3MS score or risk of cognitive decline as assessed by longitudinal change in 3MS score. Higher baseline serum phosphate was associated with higher odds of poor executive function as assessed by Trails B with fully adjusted odds ratios 1.12 (95% confidence interval: 0.83-1.52), 1.31 (0.97-1.77), and 1.45 (1.08-1.94) for men in the second, third, and fourth versus the bottom quartile (referent group) of serum phosphate (p-trend 0.007). However, higher phosphate level was not associated with risk of decline in executive function as assessed by longitudinal change in Trails B score with fully adjusted odds ratios 0.94 (95% confidence interval 0.69-1.28), 0.96 (0.70-1.32), and 1.21 (0.89-1.66) for men in the second, third, and fourth versus the bottom quartile (referent group) of serum phosphate (p-trend 0.22). CONCLUSIONS: Higher serum phosphate in older men was associated with a higher likelihood of poor executive function, but not with impaired global cognitive function or decline in executive or global cognition.
OBJECTIVE: Determine whether serum phosphate is associated with concurrent cognitive impairment and subsequent cognitive decline in older men independent of demographic covariates and atherosclerotic risk factors. METHODS: In a prospective study of 5529 men enrolled in the Osteoporotic Fractures in Men study, we measured baseline serum phosphate, baseline cognitive function, and change in cognitive function between baseline and follow-up exams an average of 4.6 years later using the Modified Mini-Mental State (3MS) Examination and Trails B. RESULTS: There was no association between serum phosphate and odds of cognitive impairment as assessed by baseline 3MS score or risk of cognitive decline as assessed by longitudinal change in 3MS score. Higher baseline serum phosphate was associated with higher odds of poor executive function as assessed by Trails B with fully adjusted odds ratios 1.12 (95% confidence interval: 0.83-1.52), 1.31 (0.97-1.77), and 1.45 (1.08-1.94) for men in the second, third, and fourth versus the bottom quartile (referent group) of serum phosphate (p-trend 0.007). However, higher phosphate level was not associated with risk of decline in executive function as assessed by longitudinal change in Trails B score with fully adjusted odds ratios 0.94 (95% confidence interval 0.69-1.28), 0.96 (0.70-1.32), and 1.21 (0.89-1.66) for men in the second, third, and fourth versus the bottom quartile (referent group) of serum phosphate (p-trend 0.22). CONCLUSIONS: Higher serum phosphate in older men was associated with a higher likelihood of poor executive function, but not with impaired global cognitive function or decline in executive or global cognition.
Authors: Kristine Yaffe; Lynn Ackerson; Manjula Kurella Tamura; Patti Le Blanc; John W Kusek; Ashwini R Sehgal; Debbie Cohen; Cheryl Anderson; Lawrence Appel; Karen Desalvo; Akinlolu Ojo; Stephen Seliger; Nancy Robinson; Gail Makos; Alan S Go Journal: J Am Geriatr Soc Date: 2010-01-26 Impact factor: 5.562
Authors: Eric Orwoll; Janet Babich Blank; Elizabeth Barrett-Connor; Jane Cauley; Steven Cummings; Kristine Ensrud; Cora Lewis; Peggy M Cawthon; Robert Marcus; Lynn M Marshall; Joan McGowan; Kathy Phipps; Sherry Sherman; Marcia L Stefanick; Katie Stone Journal: Contemp Clin Trials Date: 2005-10 Impact factor: 2.226
Authors: Isabelle Six; Julien Maizel; Fellype C Barreto; Ashraf Y Rangrez; Sébastien Dupont; Michel Slama; Christophe Tribouilloy; Gabriel Choukroun; Jean Claude Mazière; Stefanie Bode-Boeger; Jan T Kielstein; Tilman B Drüeke; Ziad A Massy Journal: Cardiovasc Res Date: 2012-07-20 Impact factor: 10.787
Authors: Sally A Shumaker; Claudine Legault; Stephen R Rapp; Leon Thal; Robert B Wallace; Judith K Ockene; Susan L Hendrix; Beverly N Jones; Annlouise R Assaf; Rebecca D Jackson; Jane Morley Kotchen; Sylvia Wassertheil-Smoller; Jean Wactawski-Wende Journal: JAMA Date: 2003-05-28 Impact factor: 56.272